LAROSA JOSEPH J 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Jan 4, 2024
Insider Transaction Report
Form 4
LAROSA JOSEPH J
SVP Gen Counsel and Secretary
Transactions
- Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-01-03−34,000→ 0 totalExercise: $399.66Exp: 2024-12-16→ Common Stock (34,000 underlying) - Tax Payment
Common Stock
2024-01-03$912.30/sh−24,493$22,344,964→ 39,543 total - Exercise/Conversion
Common Stock
2024-01-03$399.66/sh+34,000$13,588,440→ 64,036 total
Holdings
- 3,367(indirect: 2022 GRAT)
Common Stock
- 355(indirect: By 401(k))
Common Stock
Footnotes (1)
- [F1]The stock option award vests in four equal annual installments, commencing one year after the date of grant.